Company Overview and News

 
Ford (F) Issues Recall for 2017-18 GT Cars in North America

2018-10-11 zacks
Ford Motor Company (F - Free Report) is recalling roughly 200 of its 2017-18 GT vehicles due to hydraulic fluid leakage. Fluid leakage from valves placed under the car’s rear part may catch fire, when making contact with exhaustion. Roughly 194 of the affected vehicles are in North America, with 176 in the United States and 18 in Canada. All the vehicles were manufactured between December 2016 and July 2018.
AZO HZN ALSN

 
HZN / Horizon Global Corp. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Horizon Global Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 44052W104 (CUSIP NUMBER) September 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
HZN

 
HZN / Horizon Global Corp. / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-10-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Horizon Global Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 44052W104 (CUSIP NUMBER) September 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
HZN

 
Unhitch From Horizon Global

2018-09-11 seekingalpha
Horizon Global shares are not inexpensive enough to compensate investors for the risks present from this stock.
HZN

1
HZN / Horizon Global Corp. 10-Q (Quarterly Report)

2018-08-07 sec.gov - 1
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSIO
HZN

 
Horizon Global Corp 2018 Q2 - Results - Earnings Call Slides

2018-08-07 seekingalpha
The following slide deck was published by Horizon Global Corp in conjunction with their 2018 Q2 earnings call.
HZN

 
Horizon Global (HZN) Q2 Earnings and Revenues Beat Estimates

2018-08-07 zacks
Horizon Global (HZN - Free Report) just came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.
AMT HZN NHI BCRX GTLS

6
New Strong Sell Stocks for July 26th

2018-07-26 zacks
Allegiant Travel Company (ALGT - Free Report) is a provider of travel services and related products to residents of under-served cities in the United States. The Zacks Consensus Estimate for its current year earnings has been revised 4.3% downward over the last 60 days.
APU HZN DEA ALGT CBAY

1
New Strong Sell Stocks for July 20th

2018-07-20 zacks
Smiths Group plc (SMGZY - Free Report) is a technology company. The Zacks Consensus Estimate for its current year earnings has been revised 2.3% downward over the last 30 days.
KDP HZN RF SMGKF CFIN SNHY SMIN SMGZY CIWV QTS

20
New Strong Sell Stocks for July 18th

2018-07-18 zacks - 1
Core Laboratories N.V. (CLB - Free Report) is a provider of reservoir description and production enhancement services. The Zacks Consensus Estimate for its current year earnings has been revised 5.8% downward over the last 30 days.
OCUL INVVY JAKK FTRPR KWR LBRT HZN LTXB IZQVF CLB FTR

5
New Strong Sell Stocks for July 16th

2018-07-16 zacks
Adient plc (ADNT - Free Report) is a designer of a range of seating systems and components. The Zacks Consensus Estimate for its current year earnings has been revised 3.7% downward over the last 30 days.
BUD GTT ADNT HZN AHBIF

 
HZN / Horizon Global Corp. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us44052w1045_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) HORIZON GLOBAL CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 44052W104 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this c
HZN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 44052W104